Morepen Laboratories Limited (MOREPENLAB.BO)
- Previous Close
50.10 - Open
50.22 - Bid 50.94 x --
- Ask 51.05 x --
- Day's Range
49.62 - 51.40 - 52 Week Range
25.35 - 56.35 - Volume
545,754 - Avg. Volume
736,443 - Market Cap (intraday)
26.059B - Beta (5Y Monthly) 1.25
- PE Ratio (TTM)
33.99 - EPS (TTM)
1.50 - Earnings Date Apr 30, 2024 - May 1, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date Sep 18, 2002
- 1y Target Est
--
Morepen Laboratories Limited develops, manufactures, markets, and sells active pharmaceutical ingredients (APIs), formulations, and home health products in India, the United States, and internationally. The company offers APIs for anti-histaminic, anti-asthmatic, anti-lipemic, anti-hypertensive, anti-diabetic, anti-coagulant, anti-gout, anti-depressant, and anti-malarial drugs; and home diagnostic products, such as air purifiers, sphygmomanometer, blood glucose test strips, blood pressure monitors, breathe free vaporizers, stethoscopes, digital thermometers, blood glucose monitors, nebulizers, heat belts, and pulse oximeters. It also provides fever X for fever; Pain X for pain; Fiber-X, a sat isabgol; Acidity X for acidity; Burnol, first degree/minor burns cream; and formulations for nutrition and probiotics, gastroenterology, antibiotics, gynecology, anti-allergic, and central nervous system, as well as cardiology, diabetology, and nutraceuticals. The company offers over the counter products under the Dr. Morepen brand. Morepen Laboratories Limited was incorporated in 1984 and is based in Gurugram, India.
www.morepen.com1,649
Full Time Employees
March 31
Fiscal Year Ends
Sector
Related News
Performance Overview: MOREPENLAB.BO
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: MOREPENLAB.BO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: MOREPENLAB.BO
Valuation Measures
Market Cap
26.06B
Enterprise Value
25.69B
Trailing P/E
33.99
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.58
Price/Book (mrq)
3.30
Enterprise Value/Revenue
1.58
Enterprise Value/EBITDA
18.53
Financial Highlights
Profitability and Income Statement
Profit Margin
4.64%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
16.42B
Net Income Avi to Common (ttm)
761.2M
Diluted EPS (ttm)
1.50
Balance Sheet and Cash Flow
Total Cash (mrq)
578.44M
Total Debt/Equity (mrq)
3.52%
Levered Free Cash Flow (ttm)
--
Research Analysis: MOREPENLAB.BO
Company Insights: MOREPENLAB.BO
MOREPENLAB.BO does not have Company Insights